RecruitingPHASE1, PHASE2NCT07049926
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 140 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2025 – 2031
Study locations (27)
- UCSF Medical Center at Mission Bay ( Site 5008), San Francisco, California, United States
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026), Mineola, New York, United States
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York, New York, United States
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York, New York, United States
- Duke Cancer Institute ( Site 5015), Durham, North Carolina, United States
- UPMC Cancer Center/Hillman Cancer Center ( Site 5017), Pittsburgh, Pennsylvania, United States
- Centro de Estudios Clínicos SAGA ( Site 6110), Santiago, Region M. de Santiago, Chile
- Bradfordhill ( Site 6101), Santiago, Region M. de Santiago, Chile
- C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203), Strasbourg, Bas-Rhin, France
- Institut Claudius Regaud ( Site 5200), Toulouse, Haute-Garonne, France
- Centre Eugene Marquis ( Site 5205), Rennes, Ille-et-Vilaine, France
- Institut De Cancerologie De Lorraine ( Site 5204), Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
- Gustave Roussy ( Site 5202), Villejuif, Île-de-France Region, France
- Rambam Health Care Campus ( Site 5500), Haifa, Israel
- Rabin Medical Center ( Site 5502), Petah Tikva, Israel
- +12 more locations on ClinicalTrials.gov
Collaborators
Exelixis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07049926 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma